Univ.-Prof. Dr. med. Martin Schuler - Onkologie / Hämatologie, Essen - Publikationen

Ausgewählte Publikationen klinische Onkologie (2012-2016):

M. Schuler, Y.-L. Wu, V. Hirsh, K. O’Byrne, N. Yamamoto, T. Mok, S. Popat, L.V. Sequist, D. Massey, V. Zazulina, and J.C.-H. Yang: First-line afatinib versus chemotherapy in non-small-cell lung cancer patients with common epidermal growth factor receptor mutations and brain metastases. J. Thorac. Oncol. 11:380-390 (2016)

M. Schuler, J.C.-H. Yang, K. Park, J.-H. Kim, J. Bennouna, Y.-M. Chen, C. Chouaid, F. De Marinis, J.-F. Feng, F. Grossi, D.-W. Kim, X. Liu, S. Lu, J. Strausz, Y. Vinnyk, R. Wiewrodt, C. Zhou, B. Wang, V.K. Chand, and D. Planchard for the LUX-Lung 5 Investigators: Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann. Oncol. 27:417-423 (2016)

W.E.E. Eberhardt, C. Pöttgen, T. Gauler, G. Friedel, S. Veit, V. Heinrich, S. Welter, W. Budach, W. Spengler, M. Kimmich, B. Fischer, H. Schmidberger, D. De Ruysscher, C. Belka, S. Cordes, R. Hepp, D. Lütke-Brintrup, N. Lehmann, M. Schuler, K.-H. Jöckel, G. Stamatis, and M. Stuschke: Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage III A (N2) and selected III B non-small-cell lung cancer following induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J. Clin. Oncol. 33:4194-4201 (2015)

D.M. Hyman, I. Puzanov, V. Subbiah, J.E. Faris, I. Chau, J.-Y. Blay, J.S. Wolf, N.S. Raje, E.L. Diamond, A. Hollebecque, R. Gervais, M.E. Elez-Fernandez, A. Italiano, R.-D. Hofheinz, M. Hidalgo, E. Chan, M. Schuler, S.F. Lasserre, M. Makrutzki, F. Sirzen, M.L. Veronese, J. Tabanero, and J. Baselga: Vermurafenib in multiple nonmelanoma BRAFV600-mutated cancers. N. Engl. J. Med. 373:726-736 (2015)

H. Reis, T. Herold, S. Ting, K. Worm, U. Huber, D.C. Christoph, W.E. Eberhardt, K. Kostbade, S. Kasper, G. Stamatis, S. Welter, K. Darwiche, R. Karpf-Wissel, D. Theegarten, K.W. Schmid, M. Schuler*, and M. Wiesweg: HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. (*corresponding author) Lung Cancer 88:34-41 (2015)

J.C.-H. Yang, Y.-L. Wu, M. Schuler, M. Sebastian, S. Popat, N. Yamamoto, C. Zhou, C.-P. Hu, K. O’Byrne, J. Feng, S. Lu, Y. Huang, S.L. Geater, K.Y. Lee, C.-M. Tsai, V. Gorbunova, V. Hirsh, J. Bennouna, S. Orlov, T. Mok, M. Boyer, W.-C. Su, K.H. Lee, T. Kato, D. Massey, M. Shahidi, V. Zazulina, and L.V. Sequist: Effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma: outcomes of the two randomised phase III trials LUX-Lung 3 and LUX-Lung 6. Lancet Oncol. 16:141-151 (2015)

M. Schuler, J.R. Fischer, C. Grohé, S. Gütz, M. Thomas, M. Kimmich, C.-P. Schneider, E. Laack, A. Märten for the Afatinib Compassionate Use Consortium: Experience with afatinib in patients with non-small-cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Oncologist 19:1100-1109 (2014)

A.T. Shaw, D.-W. Kim, R. Mehra, D.S.W. Tan, E. Felip, L.Q.M. Chow, D.R. Camidge, J. Vansteenkiste, S. Sharma, T. De Pas, G.J. Riely, B.J. Solomon, J. Wolf, M. Thomas, M. Schuler, G. Liu, A. Santoro, Y.Y. Lau, M. Goldwasser, A.L. Boral, and J.A. Engelman: Ceritinib in ALK-rearranged non-small-cell lung cancer. New Engl. J. Med. 370:1189-1197 (2014)

F. Breitenbuecher, S. Hoffarth, K. Worm, D. Cortes-Incio, T.C. Gauler, J. Koehler, T. Herold, K.W. Schmid, L. Freitag, S. Kasper, and M. Schuler: Development of a highly sensitive and specific method for detection of circulating tumor cells harbouring somatic mutations in non-small-cell lung cancer patients. PLOS ONE 9:e85350 (2014)

S. Bauer, R.A. Hilger, T. Mühlenberg, F. Grabellus, J. Nagarajah, M. Hoiczyk, A. Reichardt, M. Ahrens, P. Reichardt, S. Grunewald, M.E. Scheulen, A. Pustowka, E. Bock, M. Schuler and D. Pink: Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Brit. J. Cancer 110:155-1162 (2014)

A. Welt, M. Tewes, B. Aktas, O. Hoffmann, M. Wiesweg, S. Ting, H. Reis, K. Worm, H. Richly, J. Hense, M.R. Palmer, B.H. Lee, J. Wendling, J. Kossow, M.E. Scheulen, C. Lehnerdt, M. Kohl, C. Derks, S. Skottky, U. Haus, K.W. Schmid, R. Kimmig, M. Schuler*, and S. Kasper: Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer. (*corresponding author) Breast Cancer Res. Treat. 142:81-88 (2013)

M. Wiesweg, S. Ting, H. Reis, K. Worm, S. Kasper, M. Tewes, A. Welt, H. Richly, J. Meiler, S. Bauer, J. Hense, T.C. Gauler, J. Köhler, W.E. Eberhardt, K. Darwiche, L. Freitag, G. Stamatis, F. Breitenbücher, J. Wohlschlaeger, D. Theegarten, C. Derks, D. Cortes-Incio, G. Linden, S. Skottky, P. Lütkes, A. Dechêne, A. Paul, P. Markus, K.W. Schmid, and M. Schuler: Feasibility of preemptive biomarker profiling for personalized early clinical drug development at a comprehensive cancer center. Eur. J. Cancer 49:3076-3082 (2013)

L.V. Sequist, J.C.-H. Yang, N. Yamamoto, K. O'Byrne, V. Hirsh, T. Mok, S.L. Geater, S. Orlov, C.-M. Tsai, M. Boyer, W.-C. Su, J. Bennouna, T. Kato, V. Gorbunova, K.H. Lee, R. Shah, D. Massay, V. Zazulina, M. Shahidi, and M. Schuler: Phase III study of afatinib or cisplatin/pemetrexed in metastatic lung adenocarcinoma patients with epidermal growth factor receptor mutations. J. Clin. Oncol. 31:3327-3334 (2013)

M. Schuler, A. Awada, P. Harter, J.L. Canon, K. Possinger, M. Schmidt, J. DeGreve, P. Neven, L. Dirix, W. Jonat, M.W. Beckmann, J. Schütte, P.A. Fasching, N. Gottschalk, T. Besse-Hamme, F. Fleischer, S. Wind, M. Uttenreuther-Fischer, M. Piccart, and N. Harbeck: A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res. Treat. 134:1149-1159 (2012)

M. Schmidt, D. Rüttinger, M. Sebastian, C.A. Hanusch, N. Marschner, P.A. Baeuerle, A. Wolf, G. Göppel, D. Oruzio, G. Schlimok, G.G. Steger, C. Wolf, W. Eiermann, A. Lang, and M. Schuler: Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann. Oncol. 23:2306-2313 (2012)